An article today mentioned that the R&D Chief "was commuting long distance from Chicago to the company's (SNTA) headquarters outside Boston", so that probably explains why he left SNTA to return to his old job. Purely personal reason. This should no longer affect the run up to ASCO.
sye, i agree. it's prudent to never count your chicks until they hatch in biotech. especially when all the isp presenting shows that g does not have good monotheraphy efficacy. the future for g will be in combo so the only presentation that matters is the one on galaxy.